1 / 7

tumor cell lysis

The target tumor cells are labeled with specific fluorescent cytoplasmic reagent, the live cells can be imaged and monitored at real-time level to measure the tumor cell lysis. The reagent is safe for cells at optimized concentration, and fluorescence measurements can be accurately performed for short-term experiments, as the reagent will be diluted with cell proliferation. In addition, the ratio of target tumor cells and CAR-T cells can be optimized in the assay. https://www.creative-biolabs.com/car-t/t-cell-mediated-tumor-cell-lysis-assay.htm

Download Presentation

tumor cell lysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Reference: https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell https://www.creative-biolabs.com/car-t/t-cell-mediated-tumor-cell-lysis-assay.htm T Cell-Mediated Tumor Cell Lysis Assay

  2. Background • Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. • CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors.

  3. Anti-tumor activity in mice is induced only when both the universal CAR T cells plus the correct antigen-specific adaptor molecules are present. Anti-tumor activity and toxicity can be controlled by adjusting the administered adaptor molecule dosing. Treatment of antigenically heterogeneous tumors can be achieved by administration of a mixture of the desired antigen-specific adaptors. Thus, several challenges of current CAR T cell therapies, such as: • the inability to control the rate of cytokine release and tumor lysis • the absence of an “off switch” that can terminate cytotoxic activity when tumor eradication is complete • a requirement to generate a different CAR T cell for each unique tumor antigen • may be solved or mitigated using this approach.

  4. Two Assays for T Cell-Mediated Tumor Cell Lysis • The target tumor cells can be incubated with the radiolabel. The specific radiolabel is taken up and reversibly binds to cytosolic proteins. When the target cells are recognized by CAR-T lymphocytes, the target cells are killed and the radiolabel is released.

  5. Two Assays for T Cell-Mediated Tumor Cell Lysis • The target tumor cells are labeled with specific fluorescent cytoplasmic reagent, the live cells can be imaged and monitored at real-time level to measure the tumor cell lysis. The reagent is safe for cells at optimized concentration, and fluorescence measurements can be accurately performed for short-term experiments, as the reagent will be diluted with cell proliferation. In addition, the ratio of target tumor cells and CAR-T cells can be optimized in the assay.

  6. Reference: https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell https://www.creative-biolabs.com/car-t/t-cell-mediated-tumor-cell-lysis-assay.htm Thanks

More Related